Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients

MLA

Masato Matsuyama, et al. “Risk Factors for Gemcitabine plus Nab-Paclitaxel-Induced Interstitial Lung Disease in Pancreatic Cancer Patients.” International Journal of Clinical Oncology, vol. 26, Nov. 2020, pp. 543–51. EBSCOhost, https://doi.org/10.1007/s10147-020-01827-2.

APA

Masato Matsuyama, Takafumi Mie, Naoki Sasahira, Takashi Sasaki, Akiyoshi Kasuga, Koshiro Fukuda, Masato Ozaka, Tsuyoshi Takeda, Takaaki Furukawa, & Yuto Yamada. (2020). Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients. International Journal of Clinical Oncology, 26, 543–551. https://doi.org/10.1007/s10147-020-01827-2

Chicago

Masato Matsuyama, Takafumi Mie, Naoki Sasahira, Takashi Sasaki, Akiyoshi Kasuga, Koshiro Fukuda, Masato Ozaka, Tsuyoshi Takeda, Takaaki Furukawa, and Yuto Yamada. 2020. “Risk Factors for Gemcitabine plus Nab-Paclitaxel-Induced Interstitial Lung Disease in Pancreatic Cancer Patients.” International Journal of Clinical Oncology 26 (November): 543–51. doi:10.1007/s10147-020-01827-2.